oral glp 1 in development A timeline of GLP- discovery and clinical development. Created Emerging Trends in the Development

Although no official contraindication exists for concurrent use, formal interaction studies are lacking

We have found a significant and clinically meaningful reduction in ICP in the treatment arm as compared to the placebo arm both acutely and after 12 weeks of dosing

Plaintiffs allege the companies misled consumers about potential side effects and safety risks associated with GLP-1 medications

Amyloid- and Tau at the Crossroads of Alzheimers Disease

An August survey by Morgan Stanley of 300 people using GLP-1 drugs for weight loss found that 77% of respondents reported visiting fast-food restaurants "less frequently," while 61% and 59% said the same about casual dining restaurants and coffee shops, respectively